At the news
? MIXEDIMPACT 6/10 8-K filed Feb 25, 2026 at 16:13 ET
OraSure Technologies reported a significant decline in Q4 and full-year 2025 revenue, down 29% and 38% respectively, driven by steep drops in its core diagnostics and sample management businesses. Despite the poor financial performance, the company highlighted new FDA submissions for a Chlamydia/Gonorrhea self-test and a urine collection device, and maintained a $40 million share buyback program. The filing presents a mixed picture of deteriorating fundamentals offset by future growth initiatives.
- Q4 2025 revenue was $26.8 million, down 29% YoY; full-year revenue was $115 million, down 38% YoY.
- Core business revenue (excluding COVID-19) declined 22% YoY in Q4 and 14% for the full year.
- GAAP net loss was $19.3 million for Q4 and $68.7 million for the full year.
- Company submitted two new applications to the FDA in December 2025 for a rapid molecular self-test for Chlamydia/Gonorrhea and a Colli-Pee at-home urine collection device.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access